AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29169294 — intervention group
Group type: EXPERIMENTAL
Intervention: Weiss Functional Impairment Rating Scale (WFIRS)
Number of subjects: 62
Study 27692128 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC group (BUD/FM 160/4.5 μg twice daily)
Number of subjects: 91
Study 27692128 — intervention group
Group type: COMPARATOR
Intervention: ICS group (budesonide 400 μg twice daily or equivalent dose of ICS)
Number of subjects: 91
Study 27692128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 27692128 — intervention group
Group type: COMPARATOR
Intervention: ICS group
Number of subjects: 91
Study 27692128 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC group
Number of subjects: 91
Study 24532526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study 24532526 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 22974412 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin glycinate (1,050.6 mg once daily for the first month, then force-titrated to twice daily for the second month)
Number of subjects: 20
Study 22974412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20349666 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (0.5‐1.3% end‐tidal)
Number of subjects: 198
Study 20349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50‐200 mg/kg/min)
Number of subjects: 198
Study 20349666 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (in women)
Number of subjects: 198
Study 20349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (in women)
Number of subjects: 198
Study 20349666 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (in men)
Number of subjects: 198
Study 20349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (in men)
Number of subjects: 198
Study 17666196 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system blockade
Number of subjects: 0
Study 17666196 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 0
Study 17356181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐cultural adaptation of study instruments
Number of subjects: 0
Study 15589485 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of simvastatin
Number of subjects: 308
Study 15589485 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin
Number of subjects: 308
Study 15589485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 10698809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (25 mg/day to 100 mg/day)
Number of subjects: 104
Study 10698809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day to 40 mg/day)
Number of subjects: 104
Study 10698809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 9083608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (1.0, 1.5, or 2.0 mg/kg/day)
Number of subjects: 0
Study 9083608 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg/day)
Number of subjects: 0
Study 9083608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1524917 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole gel
Number of subjects: 11
Study 1524917 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 11
Study 3904134 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylstilbestrol (DES)
Number of subjects: 30
Study 3904134 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Emcyt)
Number of subjects: 30
Study 3904134 — intervention group
Group type: COMPARATOR
Intervention: Both DES and Emcyt
Number of subjects: 30
Study 31678728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational cadmium exposure (measured as blood cadmium concentration)
Number of subjects: 374
Study 31678728 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal stove density (measured as density of coal-burning stoves within 5000 m of participants' apartments)
Number of subjects: 374
Study 29626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening activities (plant task)
Number of subjects: 40
Study 29626378 — intervention group
Group type: COMPARATOR
Intervention: Control task (without plants)
Number of subjects: 40
Study 26711545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis combined with topical oropharyngeal anaesthesia (HYP group)
Number of subjects: 98
Study 26711545 — intervention group
Group type: COMPARATOR
Intervention: Topical oropharyngeal anaesthesia only (CTRL group)
Number of subjects: 98
Study 25218906 — intervention group
Group type: COMPARATOR
Intervention: Olaparib monotherapy (400 mg twice daily)
Number of subjects: 90
Study 25218906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cediranib (30 mg daily) and olaparib (200 mg twice daily)
Number of subjects: 90
Study 25218906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cediranib plus olaparib)
Number of subjects: 90
Study 21618664 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI investigation during speed-accuracy strategy switching
Number of subjects: 0
Study 21175312 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg orally twice daily
Number of subjects: 5407
Study 21175312 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg subcutaneously every 24 hours
Number of subjects: 5407
Study 21175312 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5407
Study 21175312 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 5407
Study 17427536 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone tablet (Glista)
Number of subjects: 24
Study 17427536 — intervention group
Group type: COMPARATOR
Intervention: 30 mg pioglitazone tablet (Actos)
Number of subjects: 24
Study 15580607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide 25 mug twice daily
Number of subjects: 106
Study 15580607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 12530048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/mq weekly on days 1 and 8, followed by a 2-week rest; Cisplatin 80 mg/mq on day 2 of each 28-day cycle.
Number of subjects: 50
Study 12530048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin regimen
Number of subjects: 50
Study 9464215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg/day for 1 week
Number of subjects: 15
Study 9464215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 5 weeks
Number of subjects: 15
Study 9464215 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 15
Study 9464215 — intervention group
Group type: COMPARATOR
Intervention: Placebo for an additional 2 weeks
Number of subjects: 15
Study 7710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg.kg‐1
Number of subjects: 8
Study 7710018 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5.0 mg.kg‐1.min‐1
Number of subjects: 8
Study 7710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 8
Study 2708881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 186
Study 2708881 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 186
Study 795696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg of lidocaine
Number of subjects: 246
Study 795696 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 246
Study 31915807 — intervention group
Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg every 4 days for 5 doses
Number of subjects: 60
Study 31915807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sized businesses (less than 50 employees)
Number of subjects: 188
Study 31061244 — intervention group
Group type: COMPARATOR
Intervention: Medium-sized businesses (50-99 employees)
Number of subjects: 188
Study 31061244 — intervention group
Group type: COMPARATOR
Intervention: Large-sized businesses (100 or more employees)
Number of subjects: 188
Study 31061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sized businesses
Number of subjects: 188
Study 31061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Businesses overall
Number of subjects: 188
Study 30408713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 54
Study 30408713 — intervention group
Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 54
Study 27864255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored printed feedback summarising identified health needs and recommended self-management actions.
Number of subjects: 360
Study 27864255 — intervention group
Group type: COMPARATOR
Intervention: Tailored printed feedback on identified health needs after follow-up interview.
Number of subjects: 360
Study 25210473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 0.1 mg/kg
Number of subjects: 157
Study 25210473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 0.3 mg/kg
Number of subjects: 157
Study 25210473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 22362063 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.3 g/kg body weight per day) supplemented with ketoanalogues
Number of subjects: 32
Study 22362063 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.6 g/kg body weight per day)
Number of subjects: 32
Study 20622031 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP), 50/100 μg twice a day
Number of subjects: 158
Study 20622031 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 200 μg twice a day
Number of subjects: 158
Study 20622031 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP)
Number of subjects: 158
Study 20622031 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 158
Study 20622031 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP) and Fluticasone propionate (FP)
Number of subjects: 158
Study 18001568 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (Tecnis IOL)
Number of subjects: 169
Study 18001568 — intervention group
Group type: COMPARATOR
Intervention: Spherical intraocular lens
Number of subjects: 169
Study 16363616 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography
Number of subjects: 40
Study 16363616 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 40
Study 16363616 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler examinations
Number of subjects: 40
Study 16363616 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation
Number of subjects: 40
Study 12932605 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (PSDs)
Number of subjects: 6797
Study 12932605 — intervention group
Group type: COMPARATOR
Intervention: Non-potassium-sparing diuretics (non-PSDs)
Number of subjects: 6797
Study 12932605 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (PSDs) with or without non-potassium-sparing diuretics (non-PSDs)
Number of subjects: 6797
Study 10392654 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 85
Study 10392654 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed patients
Number of subjects: 85
Study 10392654 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 85
Study 8934600 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for comparing two clustered samples of censored data
Number of subjects: 0
Study 8934600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1910082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7036278 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine, cyclophosphamide, and 5‐fluorouracil once a month for 12 months)
Number of subjects: 82
Study 7036278 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (150 mg BCG once a week for 1 year)
Number of subjects: 82
Study 7036278 — intervention group
Group type: COMPARATOR
Intervention: No complementary treatment (control group)
Number of subjects: 82
Study 31020541 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Bifidobacterium tetravaccine tablets (Live) for 2 months
Number of subjects: 120
Study 31020541 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study 30119636 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cups provided to girls with training and guidance on use, puberty education, and instructions for menstrual hygiene.
Number of subjects: 192
Study 26782957 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 181
Study 26782957 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 181
Study 25364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 105
Study 25364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing education and support
Number of subjects: 105
Study 22058190 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loaded counseling (FL)
Number of subjects: 278
Study 22058190 — intervention group
Group type: COMPARATOR
Intervention: Weekly counseling
Number of subjects: 278
Study 20625319 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense antihypertensive treatment
Number of subjects: 9711
Study 20625319 — intervention group
Group type: COMPARATOR
Intervention: Less intense antihypertensive treatment
Number of subjects: 9711
Study 20625319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline systolic BP and smoking
Number of subjects: 9711
Study 20625319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cholesterol
Number of subjects: 9711
Study 20625319 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left-ventricular hypertrophy and isolated systolic hypertension
Number of subjects: 9711
Study 17638307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape surgery (TVT)
Number of subjects: 69
Study 17638307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 6 months)
Number of subjects: 69
Study 15985160 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused discussions on household cost-benefit equations in intervention communities
Number of subjects: 3344
Study 15985160 — intervention group
Group type: COMPARATOR
Intervention: Usual health promotion activities relating to immunisation in control communities
Number of subjects: 3344
Study 12409741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 37
Study 12409741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12409741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 37
Study 10374554 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative selective vascular chemotherapy with routine quantity of FAM
Number of subjects: 82
Study 8195821 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg/day orally for 6 months
Number of subjects: 111
Study 8195821 — intervention group
Group type: COMPARATOR
Intervention: Control (ALS controls)
Number of subjects: 111
Study 3035879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (0.5 microgram daily)
Number of subjects: 76
Study 3035879 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (400 IU daily)
Number of subjects: 76
Study 31293057 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐MAST videoconferencing program
Number of subjects: 148
Study 31293057 — intervention group
Group type: COMPARATOR
Intervention: standard care from a cancer counselling service
Number of subjects: 148
Study 28730331 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 62
Study 28730331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Number of subjects: 62
Study 28186943 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture booklet intervention used with a trained researcher and a carer present, used at least twice over 20 weeks.
Number of subjects: 40
Study 28186943 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group) with a booklet provided at the end of the study.
Number of subjects: 40
Study 25115507 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (split dose 2 × 3 mg kg(‐1))
Number of subjects: 6
Study 25115507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 25115507 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 6
Study 21626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (EBT) with IV C(14)[N‐methyl]‐erythromycin
Number of subjects: 20
Study 21626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine clearance test (ACL) with oral antipyrine 10 mg/kg
Number of subjects: 20
Study 21626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)/3‐weekly or 35 mg/m(2)/weekly)
Number of subjects: 20
Study 21626050 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel weekly patients
Number of subjects: 20
Study 19781877 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 113
Study 17164029 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific communication techniques delivered by GPs focused on offering a physical explanation and approaching sensitive topics indirectly.
Number of subjects: 156
Study 17164029 — intervention group
Group type: COMPARATOR
Intervention: Standard Goldberg reattribution technique used by control GPs.
Number of subjects: 156
Study 15697064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 100% inflation
Number of subjects: 15
Study 15697064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 50% inflation
Number of subjects: 15
Study 15697064 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid tyres
Number of subjects: 15
Study 15697064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 75% inflation
Number of subjects: 15
Study 11163814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Number of subjects: 313
Study 11163814 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 313
Study 9784887 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators (20 individuals)
Number of subjects: 65
Study 9784887 — intervention group
Group type: COMPARATOR
Intervention: Non‐simulators (20 individuals)
Number of subjects: 65
Study 9784887 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (25 individuals)
Number of subjects: 65
Study 8055275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytologic screening examinations
Number of subjects: 0
Study 8055275 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic screening
Number of subjects: 0
Study 8055275 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for stage I lung cancers
Number of subjects: 0
Study 8055275 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term annual screening of a high-risk population
Number of subjects: 0
Study 2841552 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise at 92% of maximal oxygen consumption
Number of subjects: 10
Study 2841552 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise at 98% of maximal oxygen consumption
Number of subjects: 10
Study 7962679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 153
Study 7962679 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 153
Study 384738 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP ventilation (1 kPa or 10 cmH2O)
Number of subjects: 40
Study 384738 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation without PEEP (control group)
Number of subjects: 40
Study 384738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PEEP and control)
Number of subjects: 40
Study 384738 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP ventilation and control
Number of subjects: 40
Study 31308037 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Number of subjects: 80
Study 31308037 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-infection treatment)
Number of subjects: 80
Study 25475768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorohexidine gel (Group 2)
Number of subjects: 301
Study 25475768 — intervention group
Group type: COMPARATOR
Intervention: 0.12% Chlorohexidine rinse (Group 1)
Number of subjects: 301
Study 23958160 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage in cavities group (DC, n = 32)
Number of subjects: 68
Study 23958160 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage group (CD, n = 36)
Number of subjects: 68
Study 21184640 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 x 140‐mm iliac screw
Number of subjects: 10
Study 21184640 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 x 140‐mm iliac screw
Number of subjects: 10
Study 21184640 — intervention group
Group type: COMPARATOR
Intervention: Supraacetabular trajectory
Number of subjects: 10
Study 21184640 — intervention group
Group type: COMPARATOR
Intervention: Anterior inferior iliac spine (AIIS) trajectory
Number of subjects: 10
Study 21184640 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth > 80 mm
Number of subjects: 10
Study 21184640 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth ≤ 80 mm
Number of subjects: 10
Study 19339319 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐CTI (brief three‐month critical time intervention)
Number of subjects: 135
Study 19339319 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 17405770 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolving Myocardial Infarction (EMI)
Number of subjects: 8309